Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CefREC: Pharmacokinetics of Rectal vs IV Ceftriaxone in Healthy Adults
NCT03895567Phase 1Suspended
- Sponsor
- University of Oxford
- Start
- Dec 2026
- Primary completion
- Dec 2026
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ceftriaxone in bacterial infection (6 arms), sponsored by University of Oxford. Primary endpoint: Bioavailability of rectal formulation at 9 months. Planned start Dec 2026; status: suspended.
02
Drugs
ceftriaxone
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03895567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895567.